Merus Labs announces execution of binding letter of intent for the licensing, registration and distribution of specific pharmaceutical products and medical devices in Canada
Merus Labs International Inc announces the execution of a binding letter of intent between its wholly owned subsidiary and Methapharm Inc. for the licensing, registration, and distribution of specific pharmaceutical products and medical devices in Canada , on an exclusive basis.
Canada's pharmaceutical intellectual property laws need major reform to encourage and protect innovation in developing new drugs, states an analysis in CMAJ.